ADC 수탁제조 시장 : 개발 단계별, 공정 구성요소별, 표적 적응증별, 항체 세대별, 항체 유래별, 항체 아이소타입별, 페이로드 유형별, 링커 유형별, 주요 지역별 - 산업 동향 및 세계 예측(-2035년)

ADC Contract Manufacturing Market by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Isotype, Type of Payload, Type of Linker, Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,868,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,016,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,169,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,760,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 ADC 수탁제조 시장 규모는 2035년까지 예측 기간 동안 13%의 CAGR로 확대되어 현재 17억 9,000만 달러에서 2035년까지 68억 8,000만 달러로 성장할 것으로 예상됩니다.

ADC 수탁제조 시장은 주로 항체약물접합체와 같은 첨단 치료법에 대한 수요 증가로 인해 크게 성장하고 있으며, 이미 20개 이상의 ADC 치료 프로그램이 여러 규제 당국으로부터 승인을 받았다는 점은 주목할 만합니다. 또한, 고형암과 혈액암을 포함한 다양한 암을 대상으로 260개 이상의 약물 요법이 임상시험에서 평가되고 있습니다. 이는 이 분야에서 이해관계자들이 광범위한 개발 노력을 기울이고 있음을 보여줍니다. 그러나 약물/링커 부작용, 독성 노출, 오염, 스케일업, 제조 시설에 대한 고비용 투자 등 ADC 생산과 관련된 문제들로 인해 제약사들은 주요 업무를 아웃소싱하는 추세입니다.

ADC 수탁제조 시장은 제약회사들이 이러한 혁신적 치료법에 대한 투자를 늘리면서 더욱 확대될 것으로 예상됩니다. 또한, ADC에 대한 수요 증가와 제약사들의 아웃소싱 선호도를 고려할 때, ADC 수탁제조 시장은 예측 기간 동안 큰 폭의 시장 성장을 이룰 것으로 예상되며, 초기 단계의 건강한 파이프라인으로 인해 이 분야의 성장은 장기적으로 지속될 것으로 예상됩니다.

세계 ADC 수탁제조 시장에 대해 조사했으며, 시장 개요와 함께 개발 단계별, 공정 구성요소별, 표적 적응증별, 항체 세대별, 항체 유래별, 항체 아이소타입별, 페이로드 유형별, 링커 유형별, 지역별 동향, 시장 진입 기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 소개

제6장 ADC 수탁 제조업체 : 시장 상황

제7장 기업 개요

• 분석 개요
• MabPlex
• Lonza
• Abzena
• GBI
• CARBOGEN AMCIS
• Millipore Sigma
• WuXi Biologics
• Catalent Pharma Solutions
• Cerbios-Pharma
• Formosa Laboratories
• Sterling Pharma Solutions
• Piramal Pharma Solutions
• AbbVie Contract Manufacturing

제8장 기업 경쟁력 분석

• 분석 개요
• 가정과 열쇠
• 조사 방법
• ADC 수탁 제조업체 : 기업 경쟁력 분석
• 주요 ADC 계약 제조업체 능력 벤치마크

제9장 ADC 수탁 제조업체 : 최근의 확대

제10장 ADC 수탁 제조업체 : 파트너십과 협업

제11장 제조인가 구입인가 의사결정

제12장 밸류체인 분석

제13장 ADC 제조 : 능력 분석

제14장 ADC 치료제 : 시장 개요

제15장 임상시험 분석

제16장 유망 파트너 분석

제17장 ADC 치료제 : 수요 분석

제18장 지역 능력 분석

제19장 매력과 경쟁력 매트릭스

제20장 ADC 수탁제조 시장

제21장 ADC 수탁제조 시장, 개발 단계별

제22장 ADC 수탁제조 시장, 프로세스 구성요소별

제23장 ADC 수탁제조 시장, 표적 적응증별

제24장 ADC 수탁제조 시장, 항체 세대별

제25장 ADC 수탁제조 시장, 항체 유래별

제26장 ADC 수탁제조 시장, 항체 아이소타입별

제27장 ADC 수탁제조 시장, 페이로드 유형별

제28장 ADC 수탁제조 시장, 링커 유형별

제29장 ADC 수탁제조 시장, 주요 지역별

제30장 상업용 ADC 수탁제조 시장

제31장 임상 ADC 수탁제조 시장

제32장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제33장 결론

제34장 인터뷰 기록

제35장 부록 I : 표형식 데이터

제36장 부록 II : 기업 및 단체 리스트

ksm

영문 목차

영문목차

ADC CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global ADC contract manufacturing market is estimated to grow from USD 1.79 billion in the current year to USD 6.88 billion by 2035, at a CAGR of 13% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Stage of Development

• Phase I
• Phase II
• Phase III
• Commercial

Process Component

• Antibody
• HPAPI / Cytotoxic Payload
• Conjugation / Linker
• Fill / Finish

Target Indication

• Solid Tumors
• Hematological Tumors
• Others

Antibody Generation

• Second Generation
• Third Generation
• Fourth Generation
• Next Generation

Antibody Origin

• Humanized
• Chimeric
• Murine
• Others

Antibody Isotype

• IgG1
• IgG4
• Others

Type of Payload

• Auristatin
• Camptothecin
• DNA Topoisomerase I Inhibitor
• Maytansinoid
• Others

Type of Linker

• Maleimide
• SMCC
• Tetrapeptide-based linker
• Valine-citrulline
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific and Rest of the World

ADC CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

The ADC contract manufacturing market is poised for significant growth, primarily driven by the growing demand for advanced therapeutic modalities, such as antibody drug conjugates. It is worth highlighting that more than 20 ADC therapeutic programs have already been approved by various regulatory agencies. In addition, more than 260 drug therapies targeting a wide range of cancers including solid tumors and hematological tumors are being evaluated in clinical trials. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. However, the challenges associated with ADC manufacturing, including drug / linker side reactions, exposure to toxicity, contamination, scale-up, and high capital investments in manufacturing facilities, have driven drug developers to outsource key operations.

As drug developers invest more in these innovative therapies, the market for ADC contract manufacturing is anticipated to expand further. Moreover, owing to the healthy early-stage pipeline, growth in this domain is expected to continue in the long-term as well. Given the increasing demand for ADCs and preference for outsourcing operations by drug developers, the ADC contract manufacturing market is likely to witness substantial market growth during the forecast period.

ADC CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the ADC contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• 1. Currently, over 30 manufacturers claim to have the required capabilities to offer contract manufacturing and conjugation services for antibody drug conjugates, worldwide.
• 2. Majority of the large contract manufacturers (50%) offer a wide range of ADC manufacturing services across all scales of operation; more than 45% of the ADC conjugation facilities are based in North America.
• 3. In pursuit of building a competitive edge, industry stakeholders are actively upgrading their existing capabilities and augmenting their service portfolios to become one-stop shops for ADC manufacturing.
• 4. Majority of the trials focused on ADC therapeutics were registered in the last two years; 57% of the total clinical trial studies are being conducted across different sites in the US.
• 5. 75% of the manufacturing agreements inked in this domain were focused on clinical and commercial manufacturing of ADCs, across different geographical regions.
• 6. ADC therapeutic developers are anticipated to forge strategic alliances with contract manufacturing service providers in order to outsource complex manufacturing operations.
• 7. Driven by the expanding pipeline of ADC therapeutics and manufacturing expertise available with contract service providers, the ADC contract manufacturing market is poised to witness significant growth in the future.
• 8. Over 80% of the current demand for ADC therapeutics is generated by commercialized therapeutics targeted for solid tumors, 45% of the demand is likely to be generated in North America.
• 9. The global installed contract ADC manufacturing capacity is spread across various geographies; over 90% of the current installed capacity is available with large contract manufacturers.
• 10. With nearly 70% of the ADC manufacturing operations currently being outsourced, we expect the market to grow at an annualized rate of over 13.8% over the next decade.
• 11. With the rise in demand for ADC therapeutics, the opportunity for ADC components including antibody, payload and linker is estimated to increase significantly during the forecast period.

ADC CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

By Stage of Development, Commercial Scale is Likely to Dominate the ADC Contract Manufacturing Market During the Forecast Period

Based on the stage of development, the global ADC contract manufacturing market is segmented into phase I, phase II, phase III and commercial. It is worth highlighting that majority of the current ADC contract manufacturing market is captured by the commercial phase (approved drug therapies) and this trend is likely to remain the same in the forthcoming years.

Currently, Antibody Segment Occupies the Largest Share in the ADC contract Manufacturing Market

Based on type of component, the global ADC contract manufacturing market is segmented into antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish. It is worth highlighting that the antibody segment is likely to dominate the market in the coming decade.

Solid Tumors Segment is Likely to Capture the Largest Share of the ADC Contract Manufacturing Market During the Forecast Period

Based on the target indications, the global ADC contract manufacturing market is segmented into solid tumors, hematological tumors and others. The anticipated success of late-stage ADC therapeutics intended for the treatment of solid tumors is likely to drive the market in the forthcoming years.

At Present, Third Generation Antibodies Occupies the Largest Share in the ADC contract Manufacturing Market

Based on the antibody generation, the antibody market is segmented into second generation, third, fourth and next generation. It is worth highlighting that the market is primarily driven by revenues generated from the manufacturing of third-generation antibodies, followed by fourth-generation antibodies. This can be attributed to the fact that 40% of the approved ADCs and most clinical-stage ADCs contain third-generation components. This trend is unlikely to change in the near future.

Chimeric Origin ADCs Segment is the Fastest Growing Segment in the ADC contract Manufacturing Market

Based on the antibody origin, the ADC contract manufacturing market is segmented into humanized, chimeric, murine and others. It is worth highlighting that, currently, ADCs utilizing human origin antibodies holds the larger share in the ADC contract manufacturing market.

IgG1 Antibody Isotype Segment is Likely to Dominate the ADC Contract Manufacturing Market During the Forecast Period

Based on the type of antibody isotype, the ADC contract manufacturing market is segmented into IgG1, IgG4 and others. Currently, the market is dominated by IgG1 antibody isotype. This can be attributed to the fact that IgG1 is the most common isotype available in the serum. Additionally, it plays a significant role in triggering an immune response through the Fc-mediated effector function, which is the primary mode of action for tumor targeting therapies.

By Type of Payload, Camptothecin Segment Occupies the Largest Share in the ADC Contract Manufacturing Market among HPAPI / Cytotoxic Payloads

Based on the type of payload, the HPAPI / payload market is segmented into auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others. Whilst the camptothecin as an ADC payload/ warheads will be the primary driver of the overall market, it is worth highlighting that the market share for maytansinoid-based ADCs among HPAPI / cytotoxic payloads is likely to grow at a relatively higher CAGR.

By Type of Linker, Maleimide is Likely to Dominate the ADC Contract Manufacturing Market During the Forecast Period

Based on the type of linker, the conjugation / linker market is segmented into Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others. Currently, Maleimide (as an ADC linker) captures the largest share in the market and this trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the ADC Contract Manufacturing Market

• AbbVie Contract Manufacturing
• Abzena
• CARBOGEN AMCIS
• Catalent Pharma Solutions
• Cerbios-Pharma
• Formosa Laboratories
• GBI
• Lonza
• MabPlex
• Millipore Sigma
• Piramal Pharma Solutions
• Sterling Pharma Solutions
• WuXi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer, BSP Pharmaceuticals
• Technical Business Development Manager, BSP Pharmaceuticals
• Chief Executive Officer & Founder, Oxford BioTherapeutics
• Ex-Chief Executive Officer, Abzena
• Chief Executive Officer & Co-Founder, Syndivia
• Chief Commercial Officer, Cerbios-Pharma
• Chief Business Officer, NBE-Therapeutics
• Executive Director, Eisai
• Chief Innovation Officer, Eisai
• Director, Business Development, Synaffix
• Ex-Director of CDMO, Pierre Fabre
• Director Corporate Development, Goodwin Biotechnology
• Director, Business Development, Catalent Pharma Solutions
• Ex-Group Product Manager, Catalent Pharma Solutions
• Business Development Manager, Cerbios-Pharma
• Ex-Head of Bioconjugates Commercial Development, Lonza
• Ex-Site Head, Piramal Pharma Solutions
• Associate Scientist, Ajinomoto Bio-Pharma Services

ADC CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

• The report features an in-depth analysis of the ADC contract manufacturing market, focusing on key market segments, including stage of development, process component, target indication, antibody generation, antibody origin, antibody isotype, type of payload, type of linker and key geographical regions.
• The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
• A comprehensive evaluation of companies involved in ADC contract manufacturing, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of ADC manufacturing service offered (antibody manufacturing, cytotoxic drugs and HPAPI manufacturing and payload synthesis, linker manufacturing, conjugation and fill / finish services), type of additional service offered (proof-of-concept studies, process development and scale-up and analytical development), scale of operation (Preclinical, clinical and commercial) and location of manufacturing facility.
• A comprehensive competitive analysis of ADC contract manufacturers, examining factors such as manufacturing strength (in terms of scale of operation and number of ADC manufacturing facilities), service strength and supplier strength.
• In-depth profiles of key industry players in ADC contract manufacturing market, focusing on company overviews, financial information (if available), manufacturing services portfolio, location of production facilities, and an insightful recent development and future outlook.
• An examination of the different expansion efforts made by ADC contract manufacturers in this field to enhance their manufacturing capabilities, since 2019. This analysis considers various factors, including the year of expansion, type of expansion, purpose of expansion (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial), location of expanded facility, type of facility and most active players (based on number of expansion initiatives).
• An analysis of partnerships established in this sector, since 2019, based on several parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, licensing agreements, manufacturing agreements, mergers, product development agreements, product development and manufacturing agreements, research agreements, technology integration agreements and others), purpose of agreement, scale of operation and most active players (in terms of number of partnerships). This section also highlights the regional distribution of partnership activity in this market.
• An insightful framework that emphasizes the key indicators and factors that need to be considered by ADC developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
• A comprehensive overview of the different stages involved in the production of antibody-drug conjugates (ADCs), including antibody manufacturing, payload production, linker creation, conjugation, and fill/finish processes, along with insights into the cost implications at each stage.
• Estimation of global ADC manufacturing / bioconjugation capacity, derived from data provided by various stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).
• An overview of the current market landscape of antibody-drug conjugates (ADCs), along with an in-depth analysis of the ADC pipeline. This analysis considers various relevant parameters, including status of development, target disease indication, therapeutic area, line of treatment, dosing frequency, type of therapy, target antigen, antibody isotype, payload / cytotoxin / warhead, type of payload and type of linker.
• Examination of completed, ongoing, and planned clinical studies of various drug conjugates based on parameters like trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
• A detailed evaluation of over 140 antibody-drug conjugate (ADC) therapy developers that are most likely to collaborate with ADC contract manufacturers. This analysis considers various relevant parameters, including developer strength (in terms of company size and its experience), pipeline maturity (in terms of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.
• Informed estimates of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on several relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
• A comprehensive regional capability assessment framework that evaluates key geographies by various parameters, including number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC bioconjugation capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.
• A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments, plotted on a 2X2 matrix.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What is the current annual demand for ADC therapeutics?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. ADC Contract Manufacturers: Market Overview
• 1.2. Market Share Insights
• 1.3. Market Segmentation Overview
• 1.4. Key Market Insights
• 1.5. Report Coverage
• 1.6. Key Questions Answered
• 1.7. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating

Foreign Exchange Risk

• 3.2.4. Recession
  • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
• 3.2.5. Inflation
  • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Key Components of ADCs
  • 5.2.1. Antibody
  • 5.2.2. Cytotoxin (Payloads)
  • 5.2.3. Linker
• 5.3. ADC Manufacturing
  • 5.3.1. Key Steps
  • 5.3.2. Technical Challenges
  • 5.3.3. Need for Outsourcing
• 5.4. Challenges Associated with Supply Chain and Method Transfer
  • 5.4.1. Growing Demand for One-Stop Shops and Integrated Service Providers
• 5.5. Selecting a CMO Partner
• 5.6. Future Perspective

6. ADC CONTRACT MANUFACTURERS: MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. ADC Contract Manufacturers: Overall Market Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters
  • 6.2.4. Analysis by Type of ADC Manufacturing Service Offered
  • 6.2.5. Analysis by Type of Additional Service Offered
  • 6.2.6. Analysis by Scale of Operation
  • 6.2.7. Analysis by Location of Manufacturing Facilities

7. COMPANY PROFILES

• 7.1. Chapter Overview
• 7.2. MabPlex
  • 7.2.1. Company Overview
  • 7.2.2. ADC Related Services
  • 7.2.3. Manufacturing Facilities
  • 7.2.4. Recent Developments and Future Outlook
• 7.3. Lonza
  • 7.3.1. Company Overview
  • 7.3.2. Financial Information
  • 7.3.3. ADC Related Services
  • 7.3.4. Manufacturing Facilities
  • 7.3.5. Recent Developments and Future Outlook
• 7.4. Abzena
  • 7.4.1. Company Overview
  • 7.4.2. ADC Related Services
  • 7.4.3. Manufacturing Facilities
  • 7.4.4. Recent Developments and Future Outlook
• 7.5. GBI
  • 7.5.1. Company Overview
  • 7.5.2. ADC Related Services
  • 7.5.3. Manufacturing Facilities
  • 7.5.4. Recent Developments and Future Outlook
• 7.6. CARBOGEN AMCIS
  • 7.6.1. Company Overview
  • 7.6.2. ADC Related Services
  • 7.6.3. Manufacturing Facilities
  • 7.6.4. Recent Developments and Future Outlook
• 7.7. Millipore Sigma
  • 7.7.1. Company Overview
  • 7.7.2. ADC Related Offerings
  • 7.7.3. Manufacturing Facilities
  • 7.7.4. Recent Developments and Future Outlook
• 7.8. WuXi Biologics
  • 7.8.1. Company Overview
  • 7.8.2. Financial Information
  • 7.8.3. ADC Related Services
  • 7.8.4. Manufacturing Facilities
  • 7.8.5. Recent Developments and Future Outlook
• 7.9. Catalent Pharma Solutions
  • 7.9.1. Company Overview
  • 7.9.2. Financial Information
  • 7.9.3. ADC Related Services
  • 7.9.4. Manufacturing Facilities
  • 7.9.5. Recent Developments and Future Outlook
• 7.10. Cerbios-Pharma
  • 7.10.1. Company Overview
  • 7.10.2. ADC Related Services
  • 7.10.3. Manufacturing Facilities
  • 7.10.4. Recent Developments and Future Outlook
• 7.11. Formosa Laboratories
  • 7.11.1. Company Overview
  • 7.11.2. ADC Related Services
  • 7.11.3. Manufacturing Facilities
  • 7.11.4. Recent Developments and Future Outlook
• 7.12. Sterling Pharma Solutions
  • 7.12.1. Company Overview
  • 7.12.2. ADC Related Services
  • 7.12.3. Manufacturing Facilities
  • 7.12.4. Recent Developments and Future Outlook
• 7.13. Piramal Pharma Solutions
  • 7.13.1. Company Overview
  • 7.13.2. ADC Related Services
  • 7.13.3. Manufacturing Facilities
  • 7.13.4. Recent Developments and Future Outlook
• 7.14. AbbVie Contract Manufacturing
  • 7.14.1. Company Overview
  • 7.14.2. ADC Related Services
  • 7.14.3. Manufacturing Facilities
  • 7.14.4. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Key

Parameters

• 8.3. Methodology
• 8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
  • 8.3.1. ADC Contract Manufacturers based in North America (Peer Group I)
  • 8.3.2. ADC Contract Manufacturers based in Europe (Peer Group II)
  • 8.3.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
• 8.4. Capability Benchmarking of Top ADC Contract Manufacturers

9. ADC CONTRACT MANUFACTURERS: RECENT EXPANSIONS

• 9.1. Chapter Overview
• 9.2. ADC Contract Manufacturers: Recent Expansions
  • 9.2.1. Analysis by Year of Expansion
  • 9.2.2. Analysis by Type of Expansion
  • 9.2.3. Analysis by Purpose of Expansion
  • 9.2.4. Analysis by Scale of Operation
  • 9.2.5. Analysis by Location of Expanded Facility
  • 9.2.6. Most Active Players: Analysis by Number of Expansions

10. ADC CONTRACT MANUFACTURERS: PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. ADC Contract Manufacturers: Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Purpose of Partnership
  • 10.3.4. Analysis by Scale of Operation
  • 10.3.5. Most Active Players: Analysis by Number of Partnerships
  • 10.3.6. Analysis by Geography
    • 10.3.6.1. Intercontinental and Intracontinental Agreements
    • 10.3.6.2. Local and International Agreements

11. MAKE VERSUS BUY DECISION MAKING

• 11.1. Chapter Overview
• 11.2. Assumptions and Key Parameters
  • 11.2.1. Scenario 1
  • 11.2.2. Scenario 2
  • 11.2.3. Scenario 3
  • 11.2.4. Scenario 4
• 11.3. Concluding Remarks

12. VALUE CHAIN ANALYSIS

• 12.1. Chapter Overview
• 12.2. ADC Development Value Chain
• 12.3. Cost Distribution across the Value Chain
  • 12.3.1. Cost Associated with Antibody Manufacturing
  • 12.3.2. Cost Associated with Payload and Linker Manufacturing
  • 12.3.3. Cost Associated with Conjugation
  • 12.3.4. Cost Associated with Fill / Finish

13. ADC MANUFACTURING: CAPACITY ANALYSIS

• 13.1. Chapter Overview
• 13.2. Key Assumptions and Methodology
• 13.3. ADC Manufacturing: Global Installed Capacity
  • 13.3.1. Analysis by Company Size
  • 13.3.2. Analysis by Location of Headquarters
  • 13.3.3. Analysis by Location of Manufacturing Facilities
    • 13.3.3.1 Analysis by Region
    • 13.3.3.2. Analysis by Country
  • 13.3.4. Analysis by Key Players

14. ADC THERAPEUTICS: MARKET OVERVIEW

• 14.1. Chapter Overview
• 14.2. Antibody Drug Conjugates: Therapies Pipeline
  • 14.2.1. Analysis by Status of Development
  • 14.2.2. Analysis by Target Disease Indication
  • 14.2.3. Analysis by Therapeutic Area
  • 14.2.4. Analysis by Line of Treatment
  • 14.2.5. Analysis by Dosing Frequency
  • 14.2.6. Analysis by Type of Therapy
  • 14.2.7. Analysis by Target Antigen
  • 14.2.8. Analysis by Antibody Isotype
  • 14.2.9. Analysis by Payload / Cytotoxin / Warhead
  • 14.2.10. Analysis by Type of Payload
  • 14.2.11. Analysis by Linker
  • 14.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
• 14.3. Antibody Drug Conjugates: Therapies to Watch
• 14.4. Concluding Remarks

15. CLINICAL TRIAL ANALYSIS

• 15.1. Chapter Overview
• 15.2. Scope and Methodology
• 15.3. Antibody Drug Conjugates: Clinical Trial Analysis
  • 15.3.1. Analysis by Trial Registration Year
  • 15.3.2. Analysis by Trial Status
  • 15.3.3. Analysis of Enrolled Patient Population by Trial Status
  • 15.3.4. Analysis by Trial Registration Year and Trial Status
  • 15.3.5. Analysis of Enrolled Patient Population by Trial Registration Year
  • 15.3.6. Analysis by Trial Phase
  • 15.3.7. Analysis of Enrolled Patient Population by Trial Phase
  • 15.3.8. Analysis by Type of Sponsor / Collaborator
  • 15.3.9. Analysis by Target Population
  • 15.3.10. Analysis by Study Design
  • 15.3.11. Most Active Industry Players: Analysis by Number of Trials
  • 15.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
  • 15.3.13. Analysis of Clinical Trials by Geography
  • 15.3.14. Analysis of Enrolled Patient

Population by Geography

16. LIKELY PARTNER ANALYSIS

• 16.1. Chapter Overview
• 16.2. Scoring Criteria and Key Assumptions
• 16.3. Scope and Methodology
• 16.4. Potential Strategic Partners based in North America
  • 16.4.1. Most Likely Partners
  • 16.4.2. Likely Partners
  • 16.4.3. Least Likely Partners
• 16.5. Potential Strategic Partners based in Europe
  • 16.5.1. Most Likely Partners
  • 16.5.2. Likely Partners
  • 16.5.3. Least Likely Partners
• 16.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
  • 16.6.1. Most Likely Partners
  • 16.6.2. Likely Partners
  • 16.6.3. Least Likely Partners

17. ADC THERAPEUTICS: DEMAND ANALYSIS

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. ADC Therapeutics: Global Annual Demand
  • 17.3.1. ADC Therapeutics: Annual Commercial Demand
    • 17.3.1.1. Analysis by Target Indication
    • 17.3.1.2. Analysis by Antibody Origin
    • 17.3.1.3. Analysis by Antibody Isotype
    • 17.3.1.4. Analysis by Type of Payload
    • 17.3.1.5. Analysis by Type of Linker
    • 17.3.1.6 Analysis by Key Geographical Regions
  • 17.3.2. ADC Therapeutics: Annual Clinical Demand
    • 17.3.2.1. Analysis by Phase of Development
    • 17.3.2.2. Analysis by Target Indication
    • 17.3.2.3. Analysis by Antibody Origin
    • 17.3.2.4. Analysis by Antibody Isotype
    • 17.3.2.5. Analysis by Type of Payload
    • 17.3.2.6. Analysis by Type of Linker
    • 17.3.2.7. Analysis by Key Geographical Regions

18. REGIONAL CAPABILITY ANALYSIS

• 18.1. Chapter Overview
• 18.2. Assumptions and Key Parameters
• 18.3. ADC Contract Manufacturing Capabilities in North America
• 18.4. ADC Contract Manufacturing Capabilities in Europe
• 18.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

19. ATTRACTIVENESS COMPETETIVENESS MATRIX

• 19.1. Chapter Overview
• 19.2. AC Matrix: Overview
  • 19.2.1. Strong Business Segments
  • 19.2.2. Average Business Segments
  • 19.2.3. Weak Business Segments
• 19.3. AC Matrix: Analytical Methodology
• 19.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
  • 19.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
  • 19.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

20. ADC CONTRACT MANUFACTURING MARKET

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Global ADC Therapeutics Market, Historical Trends and Forecasted Estimates, till 2035
• 20.4. Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
  • 20.4.1. Scenario Analysis
• 20.5. Key Market Segmentations

21. ADC CONTRACT MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. ADC Contract Manufacturing Market: Distribution by Stage of Development, Current Year, 2028 and 2035
  • 21.3.1. Phase I: Forecasted Estimates, till 2035
  • 21.3.2. Phase II: Forecasted Estimates, till 2035
  • 21.3.3. Phase III: Forecasted Estimates, till 2035
  • 21.3.4. Commercial: Forecasted Estimates, till 2035
• 21.4. Data Triangulation and Validation

22. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. ADC Contract Manufacturing Market: Distribution by Process Component, Current Year, 2028 and 2035
  • 22.3.1. Antibody: Forecasted Estimates, till 2035
  • 22.3.2. HPAPI / Cytotoxic Payload: Forecasted Estimates, till 2035
  • 22.3.3. Conjugation / Linker: Forecasted Estimates, till 2035
  • 22.3.4. Fill / Finish: Forecasted Estimates, till 2035
• 22.4. Data Triangulation and Validation

23. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. ADC Contract Manufacturing Market: Distribution by Target Indication, Current Year, 2028 and 2035
  • 23.3.1. Solid Tumors: Forecasted

Estimates, till 2035

• 23.3.2. Hematological Tumors: Forecasted Estimates, till 2035
• 23.3.3. Others: Forecasted Estimates, till 2035
• 23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY GENERATION

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. ADC Contract Manufacturing Market: Distribution by Antibody Generation, Current Year, 2028 and 2035
  • 24.3.1. Second Generation: Forecasted Estimates, till 2035
  • 24.3.2. Third Generation: Forecasted Estimates, till 2035
  • 24.3.3. Fourth Generation: Forecasted Estimates, till 2035
  • 24.3.4. Next Generation: Forecasted Estimates, till 2035
• 24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin, Current Year, 2028 and 2035
  • 25.3.1. Human Origin: Forecasted Estimates, till 2035
  • 25.3.2. Chimeric Origin: Forecasted Estimates, till 2035
  • 25.3.3. Murine Origin: Forecasted Estimates, till 2035
  • 25.3.4. Others: Forecasted Estimates, till 2035
• 25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE

• 26.1. Chapter Overview
• 26.2. Key Assumptions and Methodology
• 26.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Current Year, 2029 and 2035
  • 26.3.1. IgG1: Forecasted Estimates, till 2035
  • 26.3.2. IgG4: Forecasted Estimates, till 2035
  • 26.3.3. Others: Forecasted Estimates, till 2035
• 26.4. Data Triangulation and

Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. ADC Contract Manufacturing Market: Distribution by Type of Payload, Current Year, 2029 and 2035
  • 27.3.1. Camptothecin: Forecasted Estimates, till 2035
  • 27.3.2. Maytansinoid: Forecasted Estimates, till 2035
  • 27.3.3. Auristatin: Forecasted Estimates, till 2035
  • 27.3.4. DNA topoisomerase I inhibitor: Forecasted Estimates, till 2035
  • 27.3.5. Others: Forecasted Estimates, till 2035
• 27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. ADC Contract Manufacturing Market: Distribution by Type of Linker, Current Year, 2029 and 2035
  • 28.3.1. Maleimide: Forecasted Estimates, till 2035
  • 28.3.2. SMCC: Forecasted Estimates, till 2035
  • 28.3.3. Tetrapeptide-based linker: Forecasted Estimates, till 2035
  • 28.3.4. Valine-citrulline: Forecasted Estimates, till 2035
  • 28.3.5. Others: Forecasted Estimates, till 2035
• 28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Current Year, 2029 and 2035
  • 29.3.1. North America: Forecasted Estimates, till 2035
  • 29.3.2. Europe: Forecasted Estimates, till 2035
  • 29.3.3. Asia-Pacific and Rest of the World: Forecasted Estimates, till 2035
• 29.4. Data Triangulation and Validation

30. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET

• 30.1. Chapter Overview
• 30.2. Key Assumptions and Methodology
• 30.3. Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
  • 30.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
  • 30.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
  • 30.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035
  • 30.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
  • 30.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
  • 30.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
  • 30.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
  • 30.3.8. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035

31. CLINICAL ADC CONTRACT MANUFACTURING MARKET

• 31.1. Chapter Overview
• 31.2. Key Assumptions and Methodology
• 31.3. Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
  • 31.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035
  • 31.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
  • 31.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
  • 31.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
  • 31.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
  • 31.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
  • 31.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
  • 31.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035

32. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 32.1. Chapter Overview
• 32.2. Market Drivers
• 32.3. Market Restraints
• 32.4. Market Opportunities
• 32.5. Market Challenges
• 32.6. Conclusion

33. CONCLUDING REMARKS

34. INTERVIEW TRANSCRIPTS

• 34.1. Chapter Overview
• 34.2. Company A
  • 34.2.1. Company Snapshot
  • 34.2.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager
• 34.3. Company B
  • 34.3.1. Company Snapshot
  • 34.3.2. Interview Transcript: Chief Executive Officer and Founder
• 34.4. Company C
  • 34.4.1. Company Snapshot
  • 34.4.2. Interview Transcript: Former Chief Executive Officer
• 34.5. Company D
  • 34.5.1. Company Snapshot
  • 34.5.2. Interview Transcript: Chief Executive Officer and Co-Founder
• 34.6. Company E
  • 34.6.1. Company Snapshot
  • 34.6.2. Interview Transcript: Chief Commercial Officer
• 34.7. Company F
  • 34.7.1. Company Snapshot
  • 34.7.2. Interview Transcript: Chief Business Officer
• 34.8. Company G
  • 34.8.1. Company Snapshot
  • 34.8.2. Interview Transcript: Executive Director and Chief Innovation Officer
• 34.9. Company H
  • 34.9.1. Company Snapshot
  • 34.9.2. Interview Transcript: Director, Business Development
• 34.10. Company I
  • 34.10.1. Company Snapshot
  • 34.10.2. Interview Transcript: Former Director of CDMO
• 34.11. Company J
  • 34.11.1. Company Snapshot
  • 34.11.2. Interview Transcript: Director Corporate Development
• 34.12. Company K
  • 34.12.1. Company Snapshot
  • 34.12.2. Interview Transcript: Business Development Manager
• 34.13. Company L
  • 34.13.1. Company Snapshot
  • 34.13.2. Interview Transcript: Director, Business Development and Former Group Product Manager
• 34.14. Company M
  • 34.14.1. Company Snapshot
  • 34.14.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
• 34.15. Company N
  • 34.15.1. Company Snapshot
  • 34.15.2. Interview Transcript: Former Site Head
• 34.16. Company O
  • 34.16.1. Company Snapshot
  • 34.16.2. Interview Transcript: Associate General Manager
• 34.17. Interview Transcript: Director, Business Development, Leading CMO
• 34.18. Interview Transcript: Chief Executive Officer, Leading CMO

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료